Olanzapine Teva

Olanzapine, the active ingredient in Olanzapine Teva, is an atypical antipsychotic presented as a 10 mg tablet for oral use. It is indicated for the treatment of schizophrenia and bipolar I disorder in adults. GNH USA supplies Olanzapine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is used in psychiatric care to modulate dopaminergic and serotonergic pathways. - Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations and thought disorder. - Bipolar I disorder (manic episodes): controls acute mania and stabilises mood. - Maintenance treatment of bipolar disorder: helps prevent recurrence of manic or depressive episodes.

Olanzapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Weight gain: increased appetite leading to body mass increase. - Somnolence: drowsiness or sedation. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headed feeling, especially on standing. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe reduction in white blood cells. - Hyperglycemia/diabetes mellitus: marked elevation of blood glucose. - Tardive dyskinesia: involuntary, repetitive movements. - Leukopenia: lowered white blood cell count. - Seizures: risk of convulsive episodes.

When prescribing Olanzapine, clinicians should consider several safety measures. - Metabolic monitoring: regularly assess weight, glucose and lipid levels. - Cardiovascular risk: evaluate patients with existing heart disease. - Hypersensitivity: avoid use in individuals with known allergy to olanzapine. - Elderly dementia patients: increased risk of mortality; use with caution. - Hepatic function: adjust use in patients with liver impairment. - Store at below 25°C: keep in the original pack, protect from moisture.

Olanzapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - CNS depressants: may enhance sedation and respiratory depression. - Anticholinergic agents: can worsen anticholinergic burden. - CYP1A2 inhibitors (e.g., fluvoxamine): increase olanzapine plasma concentrations. - CYP1A2 inducers (e.g., smoking): reduce olanzapine levels, risking loss of efficacy. - QT‑prolonging drugs: may increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect. - Antidiabetic agents: may require dose adjustment due to metabolic changes. - Lithium: potential for increased neurotoxicity. - SSRIs: heightened risk of serotonin syndrome. - Anticholinergic medications: monitor for excessive anticholinergic effects.